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Graphical abstract 
 
 
 
Highlights 
 Nasal spray formulations of PTH 1-34 containing absorption enhancers, either 
Solutol® HS15, poloxamer 407, chitosan or sodium hyaluronate, did not affect the 
PTH 1-34 bioactivity when tested within an in vitro assay. 
 An intranasal formulation of PTH 1-34 containing Solutol® HS15 had comparable 
pharmacokinetics to a subcutaneous PTH 1-34 injection in the preclinical rat model. 
 A potential clinical application of PTH 1-34 spray formulation for the treatment of 
osteoporosis has been established. 
 
Abstract 
Osteoporosis treatment with PTH 1-34 injections significantly reduces the incidence of bone 
fracture. Potential further reductions in fracture rate should be observed through nasal spray 
delivery to address the poor compliance associated with patient dislike of repeated PTH 1-34 
subcutaneous injections. In vitro human osteoblast-like Saos-2 cell intracellular cAMP levels 
were used to define PTH 1-34 nasal spray formulation bioactivity. The chemically 
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synthesised PTH 1-34 had an EC50 of 0.76nM. Absorption enhancers polyethylene glycol 
(15)-hydroxystearate (Solutol® HS15), poloxamer 407, chitosan or sodium hyaluronate did 
not diminish the bioactivity of PTH 1-34 within an in vitro cell culture model (p>0.05). We 
also demonstrated the effectiveness of the transmucosal absorption enhancer Solutol® HS15 
in a nasal spray formulation using a preclinical pharmacokinetic model. In Sprague-Dawley 
rats without the absorption enhancer the uptake of PTH 1-34 into the blood via intranasal 
delivery produced a Cmax of 2.1±0.5 ng/ml compared to 13.7±1.6 ng/ml with Solutol® HS15 
enhancer (p=0.016) and a Cmax14.8±8 ng/ml in subcutaneous injections. Together these 
data illustrate that the nasal spray formulation bioactivity in vitro is not affected by the nasal 
spray absorption enhancers investigated, and the Solutol® HS15 nasal spray formulation 
had an equivalent pharmacokinetic profile to subcutaneous injection in the rat model. The 
Solutol® HS15 formulation therefore demonstrated potential as a PTH 1-34 nasal spray 
formulation for the treatment of osteoporosis. 
Keywords 
Osteoporosis, teriparatide, formulation, nasal spray, osteoblast, drug delivery 
 
1. Introduction 
Osteoporosis is a disease characterised by a reduction in bone density with corresponding 
changes in bone microarchitecture, leading to increased fracture risk particularly of the hip 
(Genant et al., 2013), vertebrae (Michalska et al., 2012) and distal radius (Genant et al., 
2010). In the UK, annually there are more than 50,000 osteoporotic hip fractures which often 
lead to more serious health consequences or mortality. 10% of these patients fail to survive 
for one month and 30% do not survive beyond one year (Abrahamsen et al., 2009; Clark et 
al., 2012). This human cost is mirrored by a health economic implication in the UK of £2 
billion per annum. When global statistics are considered the numbers escalate. For example, 
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in China there are approximately >700,000 osteoporotic hip fractures annually (Kanis et al., 
2012). 
Bisphosphonates, which reduce osteoclast-mediated bone resorption, are the principle drug 
class used to treat osteoporosis. Anabolic osteoporosis drugs induce new bone production 
through an increase in osteoblast number (Jilka et al., 2009, Jilka et al., 1999). These 
anabolic drugs are based upon parathyroid hormone (PTH 1-84, PTH 1-34, teriparatide, 
Forsteo/Forteo or Teribone™) (Baron and Hesse, 2012; Neer et al., 2001). Teriparatide 
refers to recombinant, as opposed to chemically synthesised, PTH 1-34. Whilst a sustained 
high serum concentration of PTH suppresses bone formation (Horwitz et al., 2005), 
intermittent self-administered injections stimulate bone formation (Neer et al., 2001). Hence, 
the regimen of administration is essential for obtaining the therapeutic benefit of PTH. The 
therapeutic window of PTH 1-34 for the treatment of osteoporosis is currently limited to a 24 
month period. Forsteo (US PTH 1-34, Eli Lilly) and Forteo (EU PTH 1-34, Eli Lilly) are 
currently available as a daily 20 µg subcutaneous (SC) injection. Teribone™ (Japan PTH 1-
34, Ashai Kasei) is prescribed as a once weekly 56.5 µg SC injection (Nakamura et al., 
2012). The flank is the recommended SC injection site. 
Patient compliance to self-injectable PTH 1-84 and PTH 1-34 can be poor (Black et al., 
2013; Yu et al., 2012), and some studies have shown that only 50% of patients continue 
administering the drug for 6 months after commencing treatment (Briot et al., 2009; Foster et 
al., 2011). The reasons for poor compliance to therapy are numerous, but include a dislike of 
using needles. 10% of the world’s population have a needle phobia (Jenkins, 2014). Self-
injecting can be associated with needle-stick injuries, bleeding, pain at the injection site, 
bruising and inflammation. Improved compliance to osteoporotic medicines is associated 
with lower fracture risk therefore providing a significant patient benefit (Weycker et al., 2007). 
Non-injectable delivery of PTH 1-34 for the treatment of osteoporosis is therefore an 
important unmet clinical need. 
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Orally delivered protein and polypeptide-based drugs is an attractive option although it is 
normally inefficacious, due to enzymatic degradation, acid-induced hydrolysis and low 
absorption in the gastrointestinal tract (Goldberg and Gomez-Orellana, 2003). However, 
some promising new technologies have been developed. These include Emisphere’s Eligen® 
based on co-administration with 5-CNAC and Unigene’s oral peptide delivery system 
Peptelligence® based on the use of enteric coated tablets. Reported clinical results are 
encouraging but are inferior to SC injection of PTH with neither of these technologies having 
progressed to market (Haemmerle et al., 2012; Henriksen et al., 2013; Sturmer et al., 2013). 
Intranasal delivery offers great potential but is a challenging route for proteins and peptides, 
largely because of unfavourable bioavailability and often poorly tolerated intranasal 
membrane absorption (permeation) enhancers (Brayden et al., 2012; Illum, 2012; Illum et al., 
2012; Lems and den Heijer, 2013). Both new delivery devices and intranasal mucosal 
permeation enhancers are being developed to improve nasal delivery of these large 
molecules (Djupesland, 2013; Fortuna et al., 2014; Pires et al., 2009). Together these 
advances aim to surmount the physiochemical and biological barriers previously preventing 
successful intranasal spray delivery of biological drugs. Our formulation development 
strategy focuses upon polyethylene glycol (15)-hydroxystearate (Solutol® HS15) for 
intranasal absorption-enhancement. The PTH 1-34 intranasal spray formulation is being 
developed to achieve the required pharmacokinetic profile, mimicking the pulsatile 
subcutaneous injections with an initial fast absorption profile, which has been shown to 
promote new bone formation. 
The aim of this work was to develop a PTH 1-34 Solutol® HS15 based intranasal spray 
formulation with appropriate bioactivity, pharmacokinetics and bioavailability for the 
treatment of osteoporosis in patients. We present data on the duration of the intracellular 3'-
5'-cyclic adenosine monophosphate (cAMP) cascade evoked by the addition of PTH 1-34 in 
different formulations to Saos-2 human osteoblast-like cell cultures. In addition we present 
the half maximal effective concentration to validate the in vitro human osteoblast culture 
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system. We have compared the bioactivity within an in vitro model, of a range of 
formulations and present the pharmacokinetic profiles of the Solutol® HS15 formulation 
delivered intranasally in a pre-clinical rat model. 
2. Materials and Methods 
2.1 Materials 
PTH 1-34 was chemically synthesised by Polypeptide Inc. (Torrance, CA, USA). Chitosan 
(~150 kDa) and sodium hyaluronate (620-1200 kDa) were both obtained from Novomatrix 
(USA). Solutol® HS15 (345 Da) and Poloxamer 407 (9.8-14.6 kDa) were provided by BASF 
(UK). All other reagents were purchased from Sigma, UK, unless stated. 
2.2 Tissue culture 
Saos-2 human osteoblast-like cells are a well-characterised in vitro model, previously shown 
to express PTHR1 receptors and elicit a cAMP response when treated with parathyroid 
hormone (Rodan et al., 1987). Human osteoblast-like Saos-2 cells were purchased from the 
European Collection of Cell Cultures (Salisbury, UK). Cells were cultured at 37°C, 5% CO2 in 
0.2 µm sterile filtered McCoy’s 5A, 10% foetal calf serum (FCS), 5mM -glycerophosphate, 
50 µg/ml L-ascorbic acid and media changed every 2-3 days. Experiments were performed 
within a 5-passage window. Cells were seeded at 2104 cm-2 in tissue culture plates 
(Corning, UK) and cultured at a sub-confluent density. Mineralisation was confirmed using 
alizarin red staining at days 7 and 15. Briefly, cells were washed using PBS pH7.4, fixed in 
70% ethanol, rehydrated in water and stained using 0.5% alizarin red solution. Digital 
images were captured using a Nikon Eclipse TS100 inverted microscope (Nikon 
Instruments, UK). 
2.3 In vitro bioactivity of PTH 1-34 formulations 
Saos-2 cells were exposed to; (1) Phosphate buffered saline (PBS) pH 7.4 0.5% BSA 
(basal), (2) 7.5% w/v Solutol® HS15 in acetate buffer (pH4) (representing vehicle), (3) 1 
mg/ml PTH 1-34 in acetate buffer (pH 4) (no enhancer), or 1 mg/ml PTH 1-34 drug 
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formulations with adsorption enhancer either (4) 7.5% w/v Solutol® HS15, (5) 0.5% 
poloxamer 407, (6) 0.5% chitosan, (7) 1% chitosan (8) 0.5% hyaluronate. In brief, the Solutol 
formulation was prepared by rendering Solutol HS15 molten through raising the temperature 
to 60 ⁰C. Molten Solutol® HS15 was then dissolved in pH4 0.1 M acetate buffer also at 60 
⁰C. The resulting 7.5  % w/v Solutol HS15 was allowed to cool and used to prepare the 1 
mg/ml PTH 1-34 Solutol® HS15 formulation. Similarly, the remaining 1 mg/ml PTH 1-34 
formulations were prepared using 0.5% Poloxamer, 0.5% and 1% Chitosan and 0.5% 
Hyaluronate solutions. Before exposure to the Soas-2 cell cultures the intranasal delivery 
formulations underwent a 2 stage 1 in 25,000 dilution; 1/125 in PBS/ 0.5% BSA followed by 
1/200 in McCoy’s 5A/ 0.5% BSA culture medium (Table 1). This placed formulations with 
PTH (1-34) at a suitable concentration (~10 nM) for measuring the cAMP response of Soas-
2 cells. This dilution is also representative of the dilution of the drug which occurs between 
the administration of a nasal spray formulation and exposure to the osteoblast in bone within 
a preclinical or clinical scenario. This is based upon serum concentrations and Cmax from 
human teriparatide pharmacokinetic studies (Satterwhite et al., 2010; Sturmer et al., 2013). 
Bioactivity was determined by measuring the secondary messenger cAMP produced as a 
result of PTH 1-34 binding to the PTH receptor. The Saos-2 cells were FCS-restricted for 
16h prior to simulation. Following 30 minutes incubation with 25µM rollipram in culture 
medium, the Saos-2 cells were stimulated with the PTH 1-34 formulations or controls (1-8) 
and incubated for a further 60 minutes at 37°C, 5% CO2, washed three times in PBS pH7.4 
and lysed according to manufacturer’s instructions. Samples were stored at -20°C until 
cAMP was quantified using ELISA (R&D Systems, Abingdon, UK). Cell numbers were 
normalised using PicoGreen® DNA quantification (Molecular Probes®, Invitrogen, Paisley, 
UK). 
2.4 Pre-clinical pharmacokinetic studies 
Male Sprague-Dawley rats, 250g-350g, were housed separately in the Biomedical Support 
Unit facilities at the University of Nottingham for a minimum of 7 days for acclimatisation 
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prior to the start of the experiment. Environmental temperature and relative humidity were 
maintained at 19±2 °C and 55±10 % respectively. Drinking water and a commercial 
balanced diet was supplied ad libitum. 
The intranasal formulation of 1 mg/ml PTH 1-34, 7.5% w/v Solutol® HS15, 5% w/v mannitol 
in acetate buffer (pH4) was administered to rats (100 µg/kg). A second group of rats 
received an intranasal formulation of 1mg/ml PTH 1-34, 5% w/v mannitol in acetate buffer 
without 7.5% w/v Solutol® HS15 absorption enhancer. A third group of rats received a 
formulation a 1 mg/ml PTH 1-34 dosed subcutaneously to enable the calculation of relative 
bioavailability (80 µg/kg). Rats were sedated in groups of four with 2% v/v isoflurane vapour 
which was effective for the duration of the intranasal dosing procedure. 25-3 l of the 
intranasal formulation was placed approximately 5mm into one nostril using a Gilson® 
pipette. Non-sedated rats received subcutaneous doses. All animal work was performed 
under UK Home Office Licence No. 40/3360. 
The nasal spray PTH 1-34 bioavailability was calculated relative to subcutaneous injection in 
the rat model. A longitudinal series of blood samples was collected in heparinized tubes from 
the tail vein for 3h post administration. The total amount of blood removed from each animal 
was below 7% during the whole of the experiment. Plasma was prepared by centrifugation of 
whole blood at 13,000g for 10min at room temperature. The plasma was immediately frozen 
at -20°C prior to analysis for PTH 1-34 on an Acquity UPLC with Quattro premier XE mass 
spectrometer (Waters, Elstree, UK) (Chambers et al., 2013). 
2.5 Statistical analysis 
Data were subjected to statistical analysis using Prism 6.05 (GraphPad Inc) and Excel 14.0 
(Microsoft). Normality of data was assessed using Kolmogorov-Smirnov and distribution 
plots. ANOVA was accompanied by the Dunnett’s post-hoc test. Throughout the manuscript 
p<0.05 was considered to be statistically significant. Pharmacokinetic data were processed 
using WinNonLin 5.3 (Pharsight, Certara, USA). 
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3. Results 
The fundamental phenotypic characteristic of Soas-2 cells to deposit bone mineral on 
exposure to β-glycerophosphate and ascorbic acid was confirmed by observing a positive 
Alizarin red stain (Figure 1A). Soas-2 cells proliferated, after an initial lag period of four days 
post seeding, cell numbers made a rapid linear increase over the subsequent 7 days from 
1.6105 cm-2 to 1.4106 cm-2 (Figure 1B). A longitudinal study of the production of 
intracellular cAMP by Soas-2 cells following a 10nM dose of PTH 1-34 identified at what 
time-point the cytosolic concentration was at maximum (Figure 2). The study covered the 
first 72 hours post exposure. Baseline intracellular cAMP levels were consistently negligible 
(3.3±0.4 fmol cAMP/ ng DNA). There was a rapid increase in cAMP to approximately 33-fold 
from baseline 1 minute after dosing the PTH 1-34, which increased to 99-fold by 10 minutes. 
The peak of 406±23 fmol cAMP/ng DNA was observed 60 min post PTH 1-34 dose. During 
the following 3 hours post-maximal cAMP levels decreased rapidly to 107±14 fmol cAMP/ng 
DNA. At 24h the intracellular cAMP concentration was 9.7±0.8 fmol cAMP/ng DNA, returning 
to baseline for the remainder of the experimental period. Therefore intracellular cAMP was 
assayed 1h post treatment in subsequent formulation experiments. 
The half maximal effective concentration (EC50) of the chemically synthesised PTH 1-34 was 
determined by stimulating osteoblast-like Saos-2 cells with 0.01nM - 100nM of PTH 1-34 and 
the cell lysates assayed for cAMP. Inter-well variations were normalised using DNA and 
values are presented as mean ± standard error of the mean (SEM) (Figure 3). An EC50 of 
0.76nM was calculated for PTH 1-34 in the Saos-2 cell culture system. 
The data demonstrated that none of the absorption enhancers (Solutol® HS15, poloxamer 
407, chitosan or sodium hyaluronate), which aim to promote the entry of PTH 1-34 into the 
blood from the nasal cavity, altered the bioactivity of PTH 1-34 within the cell culture system 
(p > 0.05) (Figure 4). Bioactivity was assessed by quantifying the intracellular secondary 
messenger cAMP within osteoblast-like Saos-2 cells, which express the PTHR1 receptors 
on their cell surface. Soas-2 cells exposed to the negative control PBS pH 7.4 0.5% BSA 
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quantified basal cAMP values (1.6±0.4 fmol cAMP/ ng DNA). 7.5% Solutol® HS15 (16±6.5 
fmol cAMP/ng DNA) did not differ significantly from cAMP basal (p>0.05). PTH 1-34 
formulations containing 0.5% hyaluronate (482±104 fmol cAMP/ng DNA), 0.5% poloxamer 
407 (460±70 fmol cAMP/ng DNA), 1% chitosan (405±77 fmol cAMP/ng DNA) or 0.5% 
chitosan (588±89 fmol cAMP/ng DNA) or 7.5% Solutol® HS15 (614±135 fmol cAMP/ng 
DNA) did not differ significantly from stimulation with PTH 1-34 without nasal absorption 
enhancers (369±72 fmol cAMP/ng DNA) (p>0.05). We therefore continued to the preclinical 
phase with our nasal spray formulation containing Solutol® HS15 as our in vitro study did not 
identify that it was inferior compared to formulations containing either poloxamer 407, 
chitosan or sodium hyaluronate. Indeed none of these absorption enhancers at the 
concentrations tested had an effect on the bioactivity of PTH 1-34 (p>0.05). 
The pharmacokinetic profile after the administration of PTH 1-34 is defined for the intranasal 
delivery of the formulation with and without Solutol® HS15, plus a subcutaneous PTH 1-34 
injection without Solutol® HS15 (Figure 5, Table 2). Intranasally administered PTH 1-34 
without Solutol® HS15 was poorly absorbed as identified by the low AUC value (open 
circles, AUC=140±66.5 ng/ml/min) compared to the subcutaneously administered PTH 1-34 
(squares, AUC=1432±409.7 ng/ml/min) and the intranasally administered PTH 1-34 
enhanced with Solutol® HS15 was absorbed well (closed circles, AUC=1393±226.8 
ng/ml/min). The bioavailability of intranasally delivered PTH 1-34 enhanced with Solutol® 
HS15 in rats was calculated relative to the subcutaneous dose and found to be 78%. There 
were no significant differences between the pharmacokinetic parameters of the SC injection 
and those of intranasally delivered PTH 1-34 enhanced with Solutol® HS15 as shown in 
Table 2. 
The PTH 1-34 half-life for Solutol® HS15 enhanced intranasal delivery did not differ from that 
observed for subcutaneous injection. The peak serum concentration (Cmax) of PTH 1-34 
was equivalent in subcutaneous and intranasal enhanced administrations, both being 
significantly greater than non-enhanced intranasal delivery of PTH 1-34 (p=0.016). The 
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pharmacokinetic data obtained in rats provides evidence that the Solutol® HS15 formulation 
of PTH 1-34 have potential for intranasal delivery to humans. 
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4. Discussion 
In this study the bioactivity of intranasal formulations of PTH 1-34 was demonstrated in vitro, 
using the human osteoblast-like cell line Saos-2. The data demonstrated that the intracellular 
cAMP secondary messenger response in Saos-2 cells to PTH 1-34 was not significantly 
different between PTH 1-34 alone or the PTH 1-34 within formulations containing either 
Solutol® HS15, hyaluronate, poloxamer 407 or chitosan. The osteoblastic phenotype of 
Saos-2 cells was exemplified by the production of bone mineral under controlled cell culture 
conditions, as demonstrated in Figure 1A. Soas-2 cells are a well-established cell line suited 
to investigating the response of osteoblast-like cells to PTH and its analogues. The cells 
proliferated rapidly under the culture conditions, as shown in Figure 1B. The doubling time 
during the exponential growth phase was 31h, similar to values previously published of 32 
and 37 hours (McQuillan et al., 1995; Rodan et al., 1987). Fundamentally, this cell line is 
considered suitable as an in vitro bioassay for PTH 1-34 formulation development due to the 
expression of ~100,000 PTHR1 receptors per cell (Alokail and Peddie, 2007).  
A seminal research publication by the late Gideon Rodan’s group regarding the 
characterisation of Saos-2 cells, established the EC50 of PTH 1-34 to be 2.8 nM using an 
adenylate cyclase secondary messenger assay. This assay identified the incorporation of 
tritiated adenine into cAMP, whereas in the present studies a cAMP ELISA based assay was 
used (Rodan et al., 1987). More recently Murrills et al demonstrated an EC50 of 0.62 nM in 
Saos-2 cells (Murrills et al., 2004). Our results identified an EC50 value of 0.76 nM for 
chemically synthesised PTH 1-34. Indeed, it has been reported that the sensitivity of Soas-2 
cells to PTH 1-34 increases until confluent monolayers are reached, this being in part 
attributed to less basal cAMP being produced. Basal cAMP values are subtracted prior to 
representation of cAMP intracellular concentration post stimulation. Variation in EC50 values 
between laboratories is likely to be due to differences in Saos-2 proliferation and 
differentiation states, variations in tissue culture conditions or the PTH 1-34 preparation. 
Together, the data in our in vitro studies suggest that the chemically synthesised PTH 1-34 
Figure 5 
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in the various intranasal spray formulations did not have a detrimental effect on the cAMP 
signalling pathway in human osteoblast-like Saos-2 cells, indicating that PTH bioactivity was 
not altered (Chauvin et al., 2002; Vilardaga et al., 2002). 
Several alternatives to intranasal delivery of PTH are being investigated for the purpose of 
improving patient adherence to the administration of biological drugs (Cai et al., 2014). 
Successful oral delivery requires the PTH 1-34 formulation to resist proteolysis induced by 
the harsh acidic gastric microenvironment. New oral delivery approaches such as PTH 1-34 
loaded thiolated chitosan nanoparticles and/or pegylated chitosan nanoparticles as well as 
PTH 1-34 Solutol HS 15/ labrasol emulsions have shown promise in animal models as an 
alternative administration to injection (Narayanan et al., 2013, 2014) but as yet have not 
been translated to the clinic. However, it should be born in mind when interpreting these 
results that the gastric pathway in animal models may differ significantly from that of 
humans.  
The intranasal route has proven an established route for delivery of a number of drugs to the 
general circulation and is an expanding field of research (Illum, 2012; Illum et al., 2012; 
Riese et al., 2014). A key determinant of the efficacy of a nasal spray formulation of PTH 
1-34 is the pharmacokinetics. To investigate this the rat preclinical model was used and it 
showed that serum levels of PTH 1-34 were significantly greater when Solutol® HS15 was 
included in the nasal delivery formulation. We have previously demonstrated that Solutol® 
HS15 (CriticalSorb™) is an essential formulation component for the enhancement of the 
systemic delivery of human growth hormone via the intranasal route (Illum et al., 2012). In 
those studies, the bioavailability in conscious rats of an insulin Solutol® HS15 formulation 
delivered nasally was found to be 100 % relative to a subcutaneous injection for the first two 
hours. The bioavailability of insulin in from the nasal delivery formulation without Solutol® 
HS15 was near zero (Lewis et al., 2013). Interestingly, the bioavailability of hGH in 
combination with 10% and 7.5% Solutol® HS15 after nasal administration in rats were found 
to be 49.9 % and 34.3 % respectively (Illum et al., 2012). Solutol® HS15, a mixture of mono- 
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and diesters of 12-hydroxystearate (macrogol 15-hydroxystearate) functions as a non-ionic 
surfactant with a hydrophilic-lipophilic balance (HLB) value of 14-16. Due to the amphiphilic 
nature of its components Solutol® HS15 forms micelles (CMC ~ 0.005% w/v) in solution with 
a radius of ~6.5 nm. The size of the micelles is not affected by interaction with 
peptides/proteins and importantly when co-dissolved with Solutol® HS15, the 
peptides/proteins retain their tertiary structure (Shubber et al., 2015). This indicates that 
there is no direct interaction between the micellar structures and the drug. Solutol® HS15 
has been found to work mainly by enhancing the transcellular transport of the drug across 
the mucosal membrane and is non-toxic to the mucosal tissue (Brayden et al., 2012). The 
Solutol® HS15 formulation is compliant with the European Medicines Agency guidelines on 
pharmaceutical quality of inhalation and nasal products (EMEA/CHMP/QWP/49313/2005). 
The rational regarding pursuing a formulation containing Solutol® HS15 was supported by 
data previously published investigating the effect of repeated dosing of Solutol® HS15 on the 
nasal mucosa (Illum, 2012). However this was only a pilot study in a rat model over a 5 day 
period. Further data, perhaps in a larger animal model, would be beneficial in assessing if 
there is any irritation to the nasal mucosa by the absorption enhancer Solutol® HS15 when 
dosed repeatedly over an extended period. 
Other researchers have employed nasal absorption enhancer systems to improve the nasal 
delivery of PTH. Zelos Therapeutics showed that N-dodecyl- -D-maltoside, an enhancer 
with a similar absorption enhancing mechanism to that of Solutol® HS15, was able to 
improve the nasal absorption of a cyclic PTH 1-31 analogue to 35-40% in non-human 
primates (Krause D et al., 2009). Matsumoto et al performed a clinical nasal dosing study of 
PTH 1-34 with 90 osteoporotic subjects, mean age 66.5 years, and showed nasal 
administration of 1000 µg PTH 1-34 (a 50 fold dose increase over the 20µg/daily sub 
cutaneous injection) increased lumbar bone mineral density by 2.4% in 3 months, but 
concluded greater bioavailability was needed (Matsumoto et al., 2006). 
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Clinical applications of nasal spray formulations of PTH 1-34 could be used in combination 
with other bone regeneration techniques including implanted biomaterial (Reznikov et al., 
2016). Combining bone fracture surgery with post-operative PTH 1-34 nasal spray 
prescription could improve outcome in scenarios such as Charcot arthroplasty (Pearson et 
al., 2011; Tamai et al., 2013) and in difficult to treat ankle union (Campbell et al., 2015). 
Furthermore there is potential to combine intranasal PTH 1-34 with experimental 
therapeutics such as inhibitors of osteoclast-mediated bone resorption, to develop dual 
action drug combinations for the treatment of osteoporosis. 
 
5. Conclusion 
Overall our data demonstrate the development of a novel intranasal spray formulation of 
PTH 1-34 that generates comparable bioactivity to subcutaneous injections in a preclinical 
model. This work exemplifies the potential of Solutol® HS15 (CriticalSorb™) enhanced PTH 
1-34 intranasal spray formulations as an attractive alternative to subcutaneous injections. 
The ease of use of intranasal sprays aims to increase adherence to PTH 1-34 therapy; 
increasing efficacy, patient benefit and reducing healthcare costs. Therefore the 
pharmacokinetics of the Solutol® HS15 formulation must now be addressed within a Phase I 
clinical trial to demonstrate the translation from a small animal model to man.  
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Figure 1. Human osteoblast-like Saos-2 cell mineralisation and proliferation characteristics. A 
Photomicrograph of adherent osteoblast-like cells depicting a mineralization phenotype. Alizarin red 
produces a red complex when exposed to calcium mineral deposits. Image taken after Soas-2 cells 
were cultured for 7 days within a mineralisation promoting culture media containing the active 
ingredient 5mM -glycerophosphate. This demonstrated that the cell line at the passage numbers we 
used had maintained an osteoblastic phenotype; Bar = 100µm. B Soas-2 cell population growth. 
There is a lag phase in the proliferation of Soas-2 cells following adhesion to the tissue culture plastic 
(1-4 days). When cultured in the standard medium McCoy’s 5A with 10% foetal calf serum (FCS) 
(solid circles) cells proliferate rapidly between days 4-11. Soas-2 cultured in mineralization medium 
(solid squares) containing 5 mM -glycerophosphate did not proliferate (1-11 days) (n=2, mean ± 
SEM, p<0.05). 
Figure 2. Time course of the production of the intracellular secondary messenger cAMP by 
Soas-2 cells post PTH 1-34 stimulation. Bioassay sensitivity when quantifying differences in 
intracellular cAMP concentration caused by receptor binding of PTH (1-34) is dependent on the time 
point assayed post stimulation. Mineralising Saos-2 cells were FCS-restricted for 16h prior to 30min 
incubation with 25µM rollipram in McCoy 5A. Cells were either stimulated with the 10 mM PTH 1-34 
(squares) or PBS pH 7.4 (circles) in 0.5% BSA for 72 hours at 37°C, 5% CO2. At each time point cells 
were washed three times in PBS pH7.4 and the cell lysate was quantified using ELISA (R&D 
Systems, Abingdon, UK). (n=3, mean ±SEM). 
Figure 3. Half maximal effective concentration (EC50) of PTH 1-34 stimulation on Soas-2 cell 
cAMP intracellular messenger production. Mineralising human osteoblast-like Saos-2 cells were 
FCS-restricted for 16h prior to 30min incubation with 25µM rollipram in McCoy 5A. Cells were then 
stimulated with a range of PTH 1-34 concentrations (0.01nM – 100nM) for 1 hour at 37°C, 5% CO2. At 
each time point cells were washed three times in PBS pH7.4 and the cell lysate was quantified using 
ELISA (R&D Systems, Abingdon, UK). Inter-well variation was minimised by presenting cAMP data 
normalised to DNA. An EC50 of 0.76nM was calculated for PTH 1-34 in the Saos-2 cell culture 
system. (n=3, mean ±SEM). 
Figure 4. Solutol® HS15 PTH 1-34 bioactivity in mineralising human osteoblast-like Saos-2 
cells. Basal - PBS pH 7.4 0.05% BSA. 7.5% Solutol® HS15 sodium acetate (pH 4) vehicle, 7.5% 
Solutol® HS15 + PTH 1-34 PTH, 0.5% Hyaluronate + PTH 1-34, 0.5% Poloxamer 407 + PTH 1-34, 
1% chitosan + PTH 1-34, 0.5% chitosan + PTH 1-34. Cells were stimulated with dilutions of the above 
(1/25,000) of formulations. In each case the percentage composition of formulation components are 
prior to dilution, PTH 1-34 was 1 mg/ml in the formulations prior to dilution equating to an exposure of 
~10nM per well. Intracellular cAMP was normalised to genomic DNA quantity per well. (n=3, mean 
±SEM). 
Figure 5. Pharmacokinetic profile of Solutol® HS15 intranasal administration of PTH 1-34 in 
rats. PTH 1-34 concentration in rat plasma following administration via subcutaneous and intranasal 
routes. Intranasally administered 100 µg/kg 1 mg/ml PTH 1-34 in 5% w/v mannitol within acetate 
buffer (pH4) not containing Solutol® HS15 was poorly absorbed (○).Intranasal delivery of 100 µg/kg of 
1 mg/ml PTH 1-34 in 5% w/v mannitol within acetate buffer (pH4) with 7.5% Solutol® HS15 
(●).Subcutaneous injection of 80 µg/kg 1 mg/ml PTH 1-34 without Solutol® HS15 was used to 
calculate bioavailability (■). Bioavailability of 78% for the intranasal administration of PTH 1-34 in 
Solutol® HS15 containing formulation compared to subcutaneous administration. Calculation was 
dose corrected (n=4, mean ± SD). 
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Table 1. Formulation and Soas-2 osteoblast-like cells exposure concentration 
 of drug and excipients. Three controls were included; (1) 0.5% Bovine serum albumin (BSA), (2) 
7.5% Solutol™ HS15 which was the concentration in the Solutol™ HS15 containing formulation and 
(3) 1 mg/ml PTH (1-34) alone. Formulations containing 1 mg/ml PTH (1-34) and absorption 
enhancers, 7.5% Solutol HS15, 0.5% Poloxamer, and 0.5% and 1% Chitosan, were also prepared (4-
8). Dilution of these controls and formulations were made with standard medium McCoy’s 5A with 
10% foetal calf serum (FCS) in all cases. The concentration of PTH (1-34) and excipients exposed to 
the Soas-2 cells is listed. 
 
Table 2. Pharmacokinetic parameters of PTH (1-34) administered sub-cutaneously, intranasally 
with Solutol® HS15 enhancement and intranasally with no enhancer in rats. The peak serum 
concentration (Cmax) of PTH 1-34, the time at which peak serum concentration of PTH (1-34) was 
observed (Tmax), the area under the curve (AUC) and PTH (1-34) half-life were determined. No 
statistical difference between subcutaneous injection and intranasal administrations using Solutol® 
HS15 were observed for all pharmacokinetic parameters (p>0.05). 
Table 1 
 Formulation Concentration of drug and excipient 
exposed to Soas-2 cells  
1 0.5% BSA 2x10-5 BSA 
2 7.5% Solutol HS15 3x10-4 Solutol HS15 
3 1 mg /ml PTH 1-34 10 nM PTH 
4 7.5% Solutol HS15 + 1 mg/ml PTH 1-34 3x10-4 % Solutol HS15 + 10 nM PTH 
5 
0.5% Poloxamer 407 + 1 mg/ml PTH 1-
34 
2x10-5 % Poloxamer 407 + 10 nM PTH 
6 0.5% Chitosan + 1 mg/ml PTH 1-34 2x10-5 % Chitosan + 10 nM PTH 
7 1 % Chitosan + 1 mg/ml PTH 1-34 4x10-5 % Chitosan + 10 nM PTH  
8 0.5% Hyaluronate + 1 mg/ml PTH 1-34 2x10-5 % Hyaluronate + 10 nM PTH 1-34 
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Table 2 
Pharmacokinetic 
Parameters 
Sub-cutaneous 
PTH 1-34 
Intranasal PTH 1-34 
+ Solutol® HS15 
Intranasal PTH 1-34 
– no enhancer 
Cmax (ng/ml) 14.8 ± 7.5 13.7 ± 1.6 2.1 ± 0.5 
Tmax (min) 16.3 ± 10.3 10.0 ± 5.8 13.3 ± 14.4 
AUC0-3 (min*ng/ml) 1432 ± 409.7 1393 ± 226.8 140 ± 66.5 
Half Life (min) 189.5 ± 110.0 157.0 ± 68.1 # 
Frel0-3 (%) - 78.0 7.8 
(n=4, mean ± SD) # not determined 
 
 
